# UK Geographic Atrophy (GA) Market > UK Geographic Atrophy GA Market Research Report By Age Group (Above 60 Years, Above 75 Years), By Diagnosis (Fundus Autofluorescence, Optical Coherence Tomography Angiography, Multifocal Electroretinography) andBy Therapeutic Agents Clinical Phase (Late-Stage, Phase II, Phase I, Pre-Clinical Stage, Discovery Candidates) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.53% - **2024:** $ 1,739.48 Million - **2025:** $ 1,870.46 Million - **2035:** $ 3,865 Million - **Key Players:** Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Apellis Pharmaceuticals (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) **Report ID:** MRFR/HC/49909-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-geographic-atrophy-ga-market-51667 --- ## Market Summary ## **UK Geographic Atrophy GA Market Overview** As per MRFR analysis, the UK Geographic Atrophy GA Market Size was estimated at 1.62 (USD Billion) in 2024.The UK Geographic Atrophy GA Market Industry is expected to grow from 1.75(USD Billion) in 2025 to 3 (USD Billion) by 2035. The UK Geographic Atrophy GA Market CAGR (growth rate) is expected to be around 5.022% during the forecast period (2025 - 2035). ### **Key UK Geographic Atrophy GA Market Trends Highlighted** The UK Geographic Atrophy (GA) market is witnessing significant trends driven by an aging population and rising prevalence of retinal diseases. As the UK’s demographics shift, with a growing percentage of older adults, there is an increasing demand for treatments and management of age-related macular degeneration (AMD) and GA. The UK healthcare sector is actively focusing on innovative therapies, highlighting the importance of research and development. The National Health Service (NHS) recognizes the need for improved treatment pathways for conditions like Geographic Atrophy, thereby boosting the market for novel therapeutic approaches. Moreover, advancements in diagnostic technologies are creating new opportunities in the UK GA market. The utilization of high-resolution imaging techniques and artificial intelligence in ophthalmology is facilitating early diagnosis and better monitoring of GA progression. This has the potential to enhance patient outcomes and open up avenues for personalized treatment plans. Additionally, regulatory support for the approval of new treatments is encouraging pharmaceutical companies to invest in the research of GA therapeutics, spurring market growth. In recent times, there has been a noticeable trend toward patient-centered care. Healthcare providers in the UK are emphasizing the importance of patient education and involvement in decision-making regarding their treatment options. This shift reflects a broader movement within the healthcare system that values the patient’s perspective. By addressing the growing need for awareness and support regarding Geographic Atrophy, stakeholders can better meet patient needs and capture the evolving market potential while ensuring accessibility and affordability of treatments. The combination of these trends is shaping the future landscape of the Geographic Atrophy market in the UK. Source Primary Research, Secondary Research, MRFR Database and Analyst Review ### **UK Geographic Atrophy GA Market Drivers** #### **Increasing Prevalence of Age-Related Macular Degeneration** The UK Geographic Atrophy GA Market Industry is significantly driven by the increasing prevalence of age-related macular degeneration (AMD). Reports indicate that AMD affects around 600,000 individuals in the UK, with projections suggesting this number could double by 2050, as the population ages. The National Health Service (NHS) has recognized AMD as a leading cause of blindness in people over 50, and this population is rapidly increasing due to longevity trends. Consequently, this rising patient demographic is expected to drive the demand for Geographic Atrophy treatments. Additionally, initiatives from organizations such as the Royal National Institute of Blind People (RNIB) emphasize awareness and research into AMD, further fueling the need for effective therapeutic interventions and expanding the market for Geographic Atrophy in the UK. #### **Advancements in Research and Development** The UK Geographic Atrophy GA Market Industry is witnessing significant growth driven by advancements in Research and Development in the field of ophthalmology. Notably, an increase in funding for projects targeting retinal diseases has been observed, with UK Research and Innovation (UKRI) allocating substantial grants specifically for eye health research, reflecting a commitment to combat conditions like Geographic Atrophy. Furthermore, several pharmaceutical companies, such as Novartis and Roche, are developing innovative therapies that target the underlying causes of Geographic Atrophy, thus expected to launch within the next few years. This surge in innovative treatments is projected to bring new hope to patients while driving market growth significantly. #### **Rising Awareness and Screening Programs** Rising awareness regarding Geographic Atrophy and its implications is a crucial driver for the UK Geographic Atrophy GA Market Industry. Public health campaigns led by organizations including the NHS and the Macular Society have heightened awareness of the symptoms and risks associated with macular degeneration, encouraging more individuals to seek early screening. According to surveys conducted by these organizations, awareness of AMD has increased by over 25% in the last five years, promoting early diagnosis and treatment. Through the incorporation of periodic eye examinations into routine check-ups, the UK hopes to identify vulnerable populations and, subsequently, increase the number of patients suffering from Geographic Atrophy. ## **UK Geographic Atrophy GA Market Segment Insights** ### **Geographic Atrophy GA Market Age Group Insights** The UK Geographic Atrophy GA Market significantly focuses on age groups as a primary segmentation factor, showcasing important insights, particularly in the demographic categories of individuals above 60 Years and above 75 Years. As populations in the UK continue to age, there is an increasing prevalence of age-related eye diseases such as Geographic Atrophy, which can lead to substantial vision impairment. The impact of this condition is particularly notable among individuals in the 60 years category, who experience a higher risk and greater incidence of the disease. This demographic not only represents a majority holding in terms of total patients affected but is also where most clinical focus and healthcare resources are directed, driving innovation in treatment and management practices. Furthermore, individuals 75 Years are often more susceptible, as the likelihood of developing Geographic Atrophy increases with age. This age group typically experiences a complex interplay of ocular health issues, making them a critical segment for targeted healthcare interventions and advancements in therapies. The significant growth of this market segment can be attributed to several factors, such as an increasing aging population, advancements in diagnostic technologies, and an enhanced understanding of Geographic Atrophy. Additionally, public awareness campaigns aimed at educating the elderly about eye health contribute to early detection and intervention, underscoring the relevance of these age categories in shaping the overall market dynamics. In the UK, with initiatives derived from the National Health Service aimed at improving outcomes for older adults, there is an evident push towards research and development targeting treatments that alleviate the burden of vision loss in these age groups. Given the correlation between an aging population and the rise in eye health issues, the focus on these age demographics in the UK Geographic Atrophy GA Market underscores their importance not only from a clinical perspective but also as a solid market opportunity that perpetuates ongoing research, treatment development, and patient care improvement. Source Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Geographic Atrophy GA Market Diagnosis Insights** The Diagnosis segment of the UK Geographic Atrophy GA Market is crucial for early detection and management of this retinal disease, which is notorious for leading to significant vision loss among the elderly population. Advanced imaging techniques such as Fundus Autofluorescence are pivotal for detecting changes in the retinal structure, allowing for effective monitoring of disease progression. Optical Coherence Tomography Angiography plays a significant role by providing detailed views of the retinal and choroidal vasculature without invasive procedures, enhancing the accuracy of diagnoses. Furthermore, Multifocal Electroretinography is essential for evaluating retinal function, providing invaluable data on how the disease impacts visual pathways. The increasing prevalence of Geographic Atrophy, particularly in the aging UK population, drives the demand for these diagnostic modalities. Enhanced technology and improved imaging techniques also present unique opportunities for further market growth, despite challenges related to cost and access to high-quality devices in certain healthcare settings. As health authorities in the UK focus on managing chronic ocular conditions, the emphasis on accurate diagnostic methods remains a priority in the ongoing evolution of the UK Geographic Atrophy GA Market. ### **Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Insights** The Therapeutic Agents Clinical Phase within the UK Geographic Atrophy GA Market showcases significant progress and evolution, reflecting the heightened focus on combating this condition that leads to irreversible vision loss. The segment includes various stages, each playing a critical role in the development of innovative treatment options. Late-candidates often represent the culmination of extensive Research and Development efforts, with the potential to provide effective therapies for patients suffering from Geographic Atrophy. Phase II and Phase I studies serve to further refine treatment protocols, offering insights into safety and efficacy as they progress toward larger-scale testing. The Pre-Clinical Stage involves rigorous lab research, laying the groundwork for actual clinical trials, while Discovery Candidates symbolize the early identification of novel compounds that could revolutionize treatment approaches. Each of these stages not only contributes to the advancement of the UK Geographic Atrophy GA Market industry but also reflects the commitment to addressing unmet medical needs in the aging population. This segment is essential for market growth and sets the foundation for future innovations that may lead to better patient outcomes. Overall, these combined efforts signify an optimistic trajectory for therapeutic advancements in this critical area. ## **UK Geographic Atrophy GA Market Key Players and Competitive Insights** The UK Geographic Atrophy (GA) Market is increasingly becoming competitive as the prevalence of age-related macular degeneration continues to rise, necessitating the development of innovative therapies. This condition leads to irreversible vision loss and poses significant health challenges, prompting pharmaceutical companies to invest in research and development of effective treatment options. The competitive landscape is characterized by a combination of established players and new entrants vying for market share through unique product offerings, strategic collaborations, and geographical expansions. As regulatory frameworks evolve and patient populations grow, the strategies employed by these companies will play a critical role in shaping the future of the GA market in the UK. Horizon Therapeutics has established a notable presence in the UK Geographic Atrophy Market by leveraging its specialization in rare and underserved diseases. The company's product development emphasizes a strong commitment to addressing the unmet medical needs of patients suffering from GA. Horizon Therapeutics is recognized for its strategic research initiatives, which aim to advance innovative therapies for ocular diseases, reinforcing its position within this niche segment. The company’s strengths lie in its ability to forge collaborations with research institutions, which enhances its capacity for innovation. Additionally, Horizon Therapeutics maintains a robust pipeline of potential therapies specific to GA, making it well-positioned to address upcoming challenges and capitalize on emerging opportunities in the market. Apellis Pharmaceuticals is another key player in the UK Geographic Atrophy Market, known for its commitment to delivering transformative therapies designed to improve patient outcomes. The company has developed cutting-edge treatments focused on complement inhibition, a novel approach to managing GA. Apellis Pharmaceuticals has successfully secured a foothold in the UK through its flagship product aimed at addressing the underlying pathophysiology of GA. The company has strategically engaged in partnerships and collaborations aimed at enhancing research capabilities and expanding its market reach. With a focus on innovation, Apellis Pharmaceuticals continues to strengthen its product offerings and optimize its presence in the GA landscape. Mergers and acquisitions have also played a role in boosting its capabilities, allowing the company to advance its pipeline and broaden its competitive advantage within the UK market. ### **Key Companies in the UK Geographic Atrophy GA Market Include** ## **UK Geographic Atrophy GA Market Industry Developments** The UK Geographic Atrophy (GA) market has seen significant developments in recent months. Horizon Therapeutics and Apellis Pharmaceuticals are actively involved in advancing therapies aimed at treating GA, with Apellis continuing to gain traction for its innovative complement inhibition approach. Furthermore, Novartis has recently expanded its research footprint in the UK to enhance its ocular portfolio related to retinal diseases. In terms of mergers and acquisitions, there have been no widely reported engagements involving the companies of specific interest in the UK market. Growth in market valuation has been observed, particularly with companies such as Regeneron Pharmaceuticals and Sobi, which are focusing on expanding their Research and Development efforts in the GA domain. The UK has observed a rising prevalence of GA, prompting a greater emphasis on early diagnosis and potential therapies. Over the past few years, developments in gene therapy through Iovance Biotherapeutics and others significant attention in the research environments of UK healthcare institutions. These advancements contribute to a dynamic and evolving landscape for Geographic Atrophy treatment solutions in the UK. ## **UK Geographic Atrophy GA Market Segmentation Insights** ### **Geographic Atrophy GA Market Age Group Outlook** ### **Geographic Atrophy GA Market Diagnosis Outlook** ### **Geographic Atrophy GA Market Therapeutic Agents Clinical Phase Outlook** ## Market Drivers ### Increasing Aging Population The demographic shift towards an older population in the UK is a primary driver for the geographic atrophy-ga market. As individuals age, the risk of developing age-related macular degeneration (AMD) increases significantly. Current estimates suggest that approximately 1.5 million people in the UK are affected by AMD, with a notable portion progressing to geographic atrophy. This growing patient population necessitates enhanced healthcare services and treatment options, thereby stimulating market growth. The geographic atrophy-ga market is likely to see increased demand for innovative therapies and management strategies tailored to this aging demographic. Furthermore, the rising awareness of eye health among older adults may lead to earlier diagnosis and intervention, further propelling market expansion. ### Rising Healthcare Expenditure The increasing allocation of resources towards healthcare in the UK is a significant driver for the geographic atrophy-ga market. Government spending on health services has been on the rise, with a focus on improving access to treatments for chronic conditions, including AMD. In 2025, healthcare expenditure is projected to reach approximately £200 billion, reflecting a commitment to enhancing patient care. This financial support is likely to facilitate the development and distribution of new therapies within the geographic atrophy-ga market. Additionally, as healthcare providers invest in advanced diagnostic tools and treatment options, patients may benefit from improved access to care, ultimately driving market growth. ### Growing Awareness and Education There is a notable increase in public awareness and education regarding eye health and conditions such as geographic atrophy in the UK. Campaigns aimed at educating the population about the risks and symptoms of AMD are becoming more prevalent, leading to earlier detection and treatment. This heightened awareness is likely to result in a larger patient base seeking medical advice and intervention, thereby expanding the geographic atrophy-ga market. Furthermore, healthcare professionals are increasingly prioritizing patient education, which may empower individuals to take proactive steps in managing their eye health. As a result, the market could experience a surge in demand for both diagnostic and therapeutic solutions. ### Technological Innovations in Treatment Recent advancements in treatment modalities for geographic atrophy are poised to transform the geographic atrophy-ga market. Innovative therapies, including gene therapy and novel pharmacological agents, are under investigation and show promise in slowing disease progression. The UK has seen a surge in clinical trials focusing on these cutting-edge treatments, with several candidates demonstrating efficacy in preliminary studies. For instance, the market could witness the introduction of therapies that target specific pathways involved in retinal degeneration. As these innovations gain traction, they may not only enhance patient outcomes but also attract investment into the geographic atrophy-ga market, fostering a competitive landscape that encourages further research and development. ### Regulatory Support for Innovative Therapies The regulatory environment in the UK is becoming increasingly supportive of innovative therapies for geographic atrophy. Regulatory bodies are streamlining the approval processes for new treatments, which may encourage pharmaceutical companies to invest in research and development. This trend is particularly relevant as the geographic atrophy-ga market seeks to introduce novel therapies that address unmet medical needs. The UK government has also initiated programs aimed at expediting access to breakthrough therapies, which could significantly impact market dynamics. As a result, the geographic atrophy-ga market may witness a faster introduction of effective treatments, ultimately benefiting patients and healthcare providers alike. ## Future Outlook The [Geographic Atrophy GA Market](https://www.marketresearchfuture.com/reports/geographic-atrophy-ga-market-10781) is projected to grow at a 7.53% CAGR from 2025 to 2035, driven by increasing prevalence and advancements in treatment options. **New opportunities:** - Development of targeted gene therapies for geographic atrophy - Expansion of telemedicine platforms for remote patient monitoring - Investment in AI-driven diagnostic tools for early detection By 2035, the market is expected to achieve substantial growth, driven by innovative treatment solutions. ## Segment Insights ### By Age Group: Above 60 Years (Largest) vs. Above 75 Years (Fastest-Growing) In the UK geographic atrophy-ga market, the age group of individuals above 60 years holds the largest market share, reflecting the increasing prevalence of age-related eye conditions in this demographic. This group is significantly impacted by geographic atrophy, leading to a higher demand for treatment options and supportive care. Meanwhile, the segment of individuals above 75 years is rapidly gaining traction, driven by the rising life expectancy and the subsequent growth of elderly populations requiring specialized care for geographic atrophy. The growth trends for this segment indicate a pronounced shift towards more targeted therapies and personalized care solutions as the population ages. The increasing awareness of eye health and the willingness of older adults to seek medical interventions contribute to the expansion of the market. Furthermore, advancements in treatment methodologies and support systems for the elderly are poised to strengthen this market segment, highlighting their critical role in the overall health landscape of the UK. Above 60 Years (Dominant) vs. Above 75 Years (Emerging) The segment of individuals above 60 years is characterized by a long-established presence in the UK geographic atrophy-ga market, largely due to the high incidence of age-related macular degeneration and other retinal diseases prevalent in this age group. Their dominance is supported by a well-developed network of healthcare providers and a growing range of treatment options tailored to their needs. Conversely, the emerging segment of those above 75 years is gaining prominence, reflecting a dynamic shift as healthcare systems adapt to cater to the unique challenges faced by this older cohort. This group often experiences a more severe impact from geographic atrophy, necessitating innovative therapeutic approaches and more intensive management strategies. ### By Diagnosis: Fundus Autofluorescence (Largest) vs. Optical Coherence Tomography Angiography (Fastest-Growing) In the UK geographic atrophy-ga market, the diagnosis segment is primarily dominated by Fundus Autofluorescence (FAF), which has the largest market share. This non-invasive imaging technique is critical for assessing retinal health and detecting geographic atrophy effectively. Following FAF, Optical Coherence Tomography Angiography (OCT-A) is rapidly gaining traction due to its advanced imaging capabilities that allow detailed visualization of retinal vasculature, making it essential for diagnosis. Growth trends indicate a strong shift towards technologies that enhance diagnostic accuracy. The increasing prevalence of geographic atrophy in the aging population drives the demand for advanced diagnostic methods. Innovations like OCT-A's real-time imaging and the non-invasive nature of FAF contribute significantly to their adoption, highlighting the market's dynamic evolution toward more efficient and effective diagnostic solutions. Fundus Autofluorescence (Dominant) vs. Optical Coherence Tomography Angiography (Emerging) Fundus Autofluorescence (FAF) stands out as the dominant diagnostic technique in the UK geographic atrophy-ga market, renowned for its ability to visualize the distribution of lipofuscin in retinal pigment epithelium. Its efficiency in detecting early signs of geographic atrophy makes it invaluable for timely intervention. In contrast, Optical Coherence Tomography Angiography (OCT-A) is an emerging technology that offers detailed insights into retinal blood flow without requiring dye injection. This innovative approach is gaining momentum among healthcare professionals due to its precision and ability to improve patient outcomes. As awareness and technology advance, both FAF and OCT-A are poised to play pivotal roles in enhancing diagnostic capabilities within the market. ### By Therapeutic Agents Clinical Phase: Late-Stage (Largest) vs. Phase II (Fastest-Growing) The therapeutic agents clinical phase segment in the UK geographic atrophy-ga market is characterized by varying market shares across different developmental stages. Late-stage (Phase III) agents capture the largest market share due to their advanced development and the imminent potential for approval. Phase II agents show significant promise, gradually capturing attention as their clinical efficacy becomes more established, though they remain in a comparatively smaller share of the market. Growth trends in this segment are influenced by heightened research and development investments, driving the advancement of new therapies. The push for innovative treatments to address geographic atrophy has resulted in accelerated clinical trials and increased partnerships between pharmaceutical companies and research institutions. This momentum positions Phase II agents as the fastest-growing segment, as they showcase strong pipeline potential and attract investor interest, highlighting the dynamic nature of this market area. Late-Stage (Dominant) vs. Phase II (Emerging) Late-stage (Phase III) therapeutic agents are currently the dominant force in the UK geographic atrophy-ga market, reflecting a wealth of clinical data and nearing commercialization. These agents benefit from extensive research backing, solidifying their position with healthcare providers and payers due to proven efficacy and safety profiles. In contrast, Phase II agents are emerging as significant contenders, showcasing early efficacy data and the potential for innovative treatments. These agents are often seen as the next wave of therapeutic options, possessing characteristics that may lead to favorable outcomes. As they progress through clinical trials, interest from stakeholders is anticipated to increase, making Phase II a vital segment for future developments in the therapeutic landscape. ## Competitive Benchmarking The geographic atrophy-ga market is characterized by a competitive landscape that is increasingly shaped by innovation and strategic partnerships. Key players such as Novartis (CH), Regeneron Pharmaceuticals (US), and Roche (CH) are actively pursuing strategies that emphasize research and development, aiming to enhance their product offerings and market presence. Novartis (CH) has focused on expanding its portfolio through collaborations, while Regeneron Pharmaceuticals (US) is leveraging its expertise in biologics to develop novel therapies. Roche (CH) appears to be concentrating on integrating digital health solutions into its treatment paradigms, thereby enhancing patient engagement and outcomes. Collectively, these strategies contribute to a dynamic environment where innovation is paramount, and companies are vying for leadership through differentiated offerings.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market is moderately fragmented, with several players holding significant shares, yet none dominating entirely. This fragmentation allows for a variety of approaches to treatment and patient care, fostering a competitive atmosphere where collaboration and innovation are essential for success. In October Novartis (CH) announced a strategic partnership with a leading digital health firm to develop a comprehensive platform aimed at improving patient adherence to geographic atrophy treatments. This move is significant as it not only enhances Novartis's product offering but also positions the company at the forefront of integrating technology into healthcare, potentially improving patient outcomes and satisfaction. In September Regeneron Pharmaceuticals (US) reported the initiation of a pivotal clinical trial for a new therapy targeting geographic atrophy. This trial is crucial as it underscores Regeneron's commitment to advancing treatment options and reflects the company's strategy to leverage its robust R&D capabilities. The outcome of this trial could significantly influence the competitive landscape, particularly if the therapy demonstrates superior efficacy. In August Roche (CH) launched a new digital tool designed to assist healthcare providers in monitoring patients with geographic atrophy. This initiative highlights Roche's focus on digital transformation and its potential to enhance the standard of care. By providing healthcare professionals with advanced tools, Roche aims to solidify its position as a leader in patient-centric solutions. As of November the competitive trends in the geographic atrophy-ga market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, it is likely that competitive differentiation will evolve, shifting from traditional price-based competition to a focus on technological advancements, innovative therapies, and reliable supply chains. This transition may redefine how companies engage with healthcare providers and patients, ultimately shaping the future of the market. ## Recent News & Developments The UK Geographic Atrophy (GA) market has seen significant developments in recent months. Horizon Therapeutics and Apellis Pharmaceuticals are actively involved in advancing therapies aimed at treating GA, with Apellis continuing to gain traction for its innovative complement inhibition approach. Furthermore, Novartis has recently expanded its research footprint in the UK to enhance its ocular portfolio related to retinal diseases. In terms of mergers and acquisitions, there have been no widely reported engagements involving the companies of specific interest in the UK market. Growth in market valuation has been observed, particularly with companies such as Regeneron Pharmaceuticals and Sobi, which are focusing on expanding their Research and Development efforts in the GA domain. The UK has observed a rising prevalence of GA, prompting a greater emphasis on early diagnosis and potential therapies. Over the past few years, developments in gene therapy through Iovance Biotherapeutics and others significant attention in the research environments of UK healthcare institutions. These advancements contribute to a dynamic and evolving landscape for Geographic Atrophy treatment solutions in the UK. ## Report Scope | MARKET SIZE 2024 | 1739.48(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1870.46(USD Million) | | MARKET SIZE 2035 | 3865.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.53% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Regeneron Pharmaceuticals (US), Roche (CH), Bayer (DE), Alcon (CH), Apellis Pharmaceuticals (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE) | | Segments Covered | Age Group, Diagnosis, Therapeutic Agents Clinical Phase | | Key Market Opportunities | Advancements in gene therapy and digital health solutions enhance treatment options in the geographic atrophy-ga market. | | Key Market Dynamics | Rising demand for innovative therapies drives competition and regulatory scrutiny in the geographic atrophy market. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the market valuation for geographic atrophy in the UK in 2024?** A: The market valuation for geographic atrophy in the UK was $1739.48 Million in 2024. **Q: What is the projected market valuation for geographic atrophy in the UK by 2035?** A: The projected market valuation for geographic atrophy in the UK is $3865.0 Million by 2035. **Q: What is the expected CAGR for the UK geographic atrophy market during the forecast period 2025 - 2035?** A: The expected CAGR for the UK geographic atrophy market during the forecast period 2025 - 2035 is 7.53%. **Q: Which age group represents the highest market valuation for geographic atrophy in the UK?** A: The age group 'Above 60 Years' represented a market valuation of $1040.0 Million in 2024. **Q: What diagnostic method had the highest market valuation for geographic atrophy in the UK in 2024?** A: The diagnostic method 'Optical Coherence Tomography Angiography (OCT-A)' had a market valuation of $700.0 Million in 2024. **Q: What are the key players in the UK geographic atrophy market?** A: Key players in the UK geographic atrophy market include Novartis, Regeneron Pharmaceuticals, Roche, Bayer, Alcon, Apellis Pharmaceuticals, Santen Pharmaceutical, and Horizon Therapeutics. **Q: What was the market valuation for late-stage therapeutic agents in the UK geographic atrophy market in 2024?** A: The market valuation for late-stage (Phase III) therapeutic agents in the UK geographic atrophy market was $1040.0 Million in 2024. **Q: How does the market valuation for the 'Above 75 Years' age group compare to the 'Above 60 Years' age group?** A: The market valuation for the 'Above 75 Years' age group was $699.48 Million, which is lower than the $1040.0 Million for the 'Above 60 Years' age group in 2024. **Q: What was the market valuation for pre-clinical stage and discovery candidates in the UK geographic atrophy market in 2024?** A: The market valuation for pre-clinical stage and discovery candidates was $119.48 Million in 2024. **Q: What is the projected growth trend for the UK geographic atrophy market from 2025 to 2035?** A: The UK geographic atrophy market is projected to grow significantly, reaching $3865.0 Million by 2035, indicating a robust growth trend. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-geographic-atrophy-ga-market-51667*